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DOMESTIC ANIMALS: A SURVEY 
Andrew N. Rowan 
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Introduction 
A variety of techniques have been proposed and employed for the 
killing of domestic animals but relatively few have survived as suitable 
agents for euthanasia-namely, the induction of painless, suffering-free 
death. Some agents, such as strychnine, curariform agents, or potassium 
salts cause suffering while others have other disadvantages. 'lbday, dogs 
and cats are commonly euthanatized with sodium pentobarbital or with 
T-61 which is a mixture of a central nervous system narcotic, a paralytic 
agent, and a local anesthetic. The use of T-61 was first reported in the 
United States in 1963 (Quin 1963). The substance gradually became 
more popular because it was not a DEA-controlled substance and there-
fore practitioners did not have to deal with the stringent reporting 
requirements needed for the barbiturates. However, the presence of a 
paralytic agent in the T-61 mixture, continuing anecdotal reports of 
bad reactions when using T-61, and the relatively complicated protocol 
recommended for its administration have resulted in repeated questions 
being raised about the appropriateness ofT-61 as a euthanasia agent. 
History of T-61. Use and Evaluation 
The first reported use of T-61 for the killing of dogs and cats came 
from West Germany where Eikmeier (1961) concluded from experience 
on 350 dogs and 300 cats that the material was suitable for small 
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animal euthanasia. According to Carding (1977), T-61 use then spread in 
Europe, in part because it was cheaper than commercial solutions ofbarbit-
urate. In America, T-61 use spread more slowly. For example, the 1972 
AVMA Panel on Euthanasia did not mention the agent in its report 
(AVMA 1972), although it was included in the 1978 revision (AVMA1978). 
Although there was some unpublished electroencephalogram data 
on T-61 effects in the rats-the EEG became isoelectric in four seconds 
(Carding 1977)-no studies on the dog were reported until1978 when 
the relative effectiveness of T-61 and sodium pentobarbital were com-
pared (Lumb et al. 1978). Nine dogs were injected with T-61 and twelve 
with sodium pentobarbital under carefully controlled conditions includ-
ing the recording of EEGs and ECGs. The response of the animals to 
T-61 and sodium pentobarbital was similar except for three dogs receiv-
ing barbiturate in which cardiac output resumed. However, as Reilly 
(1978) noted, the dose of barbiturate used was close to the minimum 
lethal dose and the sodium pentobarbital solution was one-half to one-
third the strength (at 130 mg/ml) of barbiturate solutions commonly 
sold for animal euthanasia today (Lumb and Moreland 1982). 
The Survey 
In view of the continuing questions surrounding the use of T-61 
for dog and cat euthanasia, it was decided to survey the reported experi-
ence of veterinarians with the agent. Four hundred and twenty-three 
questionnaires were distributed to veterinarians in Massachusetts. 'IWo 
hundred and thirty-four completed forms were received. This represents 
a 55.3 percent response rate, which is excellent. 
Over 90 percent of the respondents indicated some experience with 
T-61 but the majority used sodium pentobarbital for routine euthanasia 
(table 1). Half of the respondents said they did not use T-61, usually 
because of one or more bad experiences with the drug. Of the rest, 27.8 
percent felt the drug was a satisfactory euthanasia agent (several felt 
it was excellent) while 21.4 percent had no strong opinion either way. 
Table 2 provides a more detailed breakdown of the opinions. 
Thble L Summary of sample responses. 
Number % of'lbtal 
Routinely use Na Pent 162 69.2 
Routinely use T-61 72 30.8 
Attitude to T-61 Pro 65 27.8 
Con(cost) 14 6.0 
Con (bad reactions) 103 44.0 
Neutral/No opinion 52 22.2 
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Thble 2. Opinions on T-61 use 
Na Pent Users T-61 Users 'lbtal 
No. % No. % No. % 
No stated opinion 22 13.6 1 1.4 23 9.8 
T-61 too expensive 14 8.6 14 6.0 
Neutral on T-61 use 27 16.7 2 2.8 29 12.4 
T-61 causes too many 
bad reactions 99 61.1 4 5.6 103 44.0 
Satisfied with or preferT-61 65 90.2 65 27.8 
TOTALS 162 100 72 100 234 100 
There were a number of comments on some of the perceived prob-
lems with T-61. Both users and non-users commented that the heart 
takes a long time to stop beating. Some talked of the heart continuing 
for as long as five minutes or more after brain death had apparently 
occurred. One respondent noted that, in 90 percent of cases, the heart 
continued beating for several minutes. Another feature of T-61 
euthanasia that was mentioned by both groups was the presence of 
muscle tremors and excitation. T-61 users did not make very much of 
this and indicated that tremors occurred in approximately 10 percent 
of cases. However, barbiturate users who did not like the drug spoke 
of excitation, including convulsions, crying and agonal thrashing, in 20 
percent or more of cases. 
Of those opposed to the use of T-61, one commented that, while 
the drug does kill the animal, it is not euthanasia. Another argued 
that T-61's relatively narrow procedural tolerance, relatively high inci-
dence of adverse reactions, and demonstrated severe excitement reac-
tions in large animals make the drug a liability. A third stated that, 
while the esthetics of barbiturate euthanasia are not always good, they 
are usually better than those associated with T-61 euthanasia. On the 
other side, one person commented that, after fifty years of experience, 
T-61 was by far the best euthanasia agent or method that has been 
made available. Another noted that T-61 is an effective euthanasia agent 
although it would be reassuring to know what it is actually doing in 
the animal. 
There were a number of contradictory comments on specific aspects 
of T-61 use. Several respondents noted that they had no problems with 
T-61 because they only used the drug for equine or large animal 
euthanasia. Others said that the drug was definitely not satisfactory 
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for equine euthanasia. Some noted that extra-venous injection of T-61 
was very painful and ineffective while others said that intracardiac, 
intrathoracic, or intraperitoneal injections were effective and did not 
cause pain. Several respondents argued that one had to use double or 
triple the recommended dose and there was a wide variation on the 
question of whether or not T-61 should be administered according to 
the manufacturer's instructions-namely, two-thirds of the dose should 
be administered slowly (one milliliter/5 seconds) and the remainder 
injected rapidly. Table 3 indicates the range of opinions on this matter. 
In one response, it was noted that a double dose of T-61 injected very 
rapidly was satisfactory while small doses injected slowly were not. 
Thble 3. Opinions on importance of injecting first two-thirds of T-61 dose slowly. 
T-61 Users NaPentUsers* All 
No. % No. % No. % 
Very Important 26 36.1 13 46.4 39 39 
Moderately Important 20 27.8 9 32.1 29 29 
Not Important 26 36.1 6 21.4 32 32 
TOTALS 72 100 28 100 100 100 
*Many of those (numbering 134 respondents) who were not using T-61 did not complete 
the section of the questionnaire dealing with the rate of injection. 
The questionnaire results also demonstrated a wide range of opinion 
on the cost issue. T-61 users were evenly divided on whether the agent 
was more expensive or less expensive to use than other euthanasia 
products. Barbiturate users who responded on this question indicated 
that T-61 was more expensive. According to one survey of suppliers, 
T-61 is considerably more expensive than Fatal-Plus or Euthanasia-6 
but about the same price as Beuthanasia-D (Barocio 1983). This is 
confirmed by Lumb and Moreland (1982) who note that the cost per 
pound to euthanize an animal with T-61 or Beuthanasia is about three 
to four times that of the simpler pentobarbital products. 
During analysis of the questionnaires, it often seemed as though 
respondents were reporting on two different drugs, so contradictory 
were some of the responses and comments. Part of the reason for this 
may well be due to the fact that T-61 administration does have narrow 
procedural tolerances and slight differences in technique may produce 
large differences in reported responses. Some of the reports appear to 
contradict the published results of Lumb et al. (1978) who noted that 
the ECG activity lasted longer in the barbiturate-injected dogs than in 
those receiving T-61. There were a number of reports of the heartbeat 
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continuing for up to a minute or more by respondents who had used 
T-61 and some uneasiness was expressed over this. 
While there are some problems with the survey (self-reporting is 
not as reliable as recorded observations), and the questionnaire did not 
identify precisely how much experience individuals had had with T-61 
(it is possible that some comments were based on very limited experi-
ence), it is possible to draw some conclusions. For example, it is clear 
that T-61 is not always used in the clinic according to the manufacturer's 
recommendations. It is also clear that there are many questions about 
T-61 that still need to be resolved. For example, what is the clinical 
incidence of muscle tremors and/or convulsions and what causes them? 
Is the prolonged duration of the heartbeat after the injection a problem 
that needs to be addressed? What is the reason for contradictory reports 
of T-61 euthanasia in large animals? This survey cannot answer such 
questions but merely adds to the anecdotal data indicating that the 
continuing use of T-61 as a euthanasia agent needs to be subjected to 
close and critical review. 
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Editor's Commentary 
Euthanasia means a humane death. For euthanasia to be humane, 
therefore, it must induce unconsciousness, not arrest respiration before 
unconsciousness occurs, and bring about the onset of death swiftly and 
consistently. 
T-61 cannot be regarded as a suitable euthanasia agent because it 
fails to meet this second criterion, namely, consistency. T-61 does not act 
consistently: it can cause animals intense pain soon after initial admin-
istration, or even a curare-like paralysis of respiration before the animal 
. . 
rs unconscwus. 
If T-61 were consistent in its pharmacological effects and caused 
death swiftly and without pain or distress to animals, then veterinarians 
would be consistent in their recognition and acceptance of T-61 as a 
humane compound for euthanasia. But the truth is that there is no 
unanimous consensus in the veterinary profession to this end as evi-
denced by Andrew Rowan's survey. 
That only 27.8 percent of respondents approved of T-61 and 44 
percent experienced bad reactions in animals to this compound is clear 
evidence that T-61 does not meet the humane euthanasia criterion of 
consistency or reliability. 
Bad reactions reported by veterinarians in Rowan's study included: 
muscle tremors and excitation, including convulsions, crying, and agonal 
thrashing; and prolonged heart activity, the heart beating for five minutes 
or longer after brain death had apparently occurred. 
The manufacturers will claim that such undesirable reactions occur 
because the veterinarians have not followed their printed instructions 
for proper administration ofT-61. But surely so many veterinarians who 
are opposed to the use ofT-61 in Rowan's survey cannot be that illiterate 
and incompetent as to be incapable of administering T-61 properly. 
Furthermore, since the manufacturers clearly admit that improper 
administration can result in inhumane side-effects on animals, it is 
self-evident that since competent and experienced veterinarians have 
had problems with this compound, animal shelter and animal control 
personnel using T-61 are likely to encounter problems even more frequently. 
Thus T-61 should not be approved for use by laypersons in animal 
shelters and it is for these reasons that The Humane Society of the 
United States (HSUS) has concluded in a recent publication that "T-61 
is an impractical and unacceptable euthanasia drug. It is not a controlled 
substance, but it is one of the more expensive euthanasia drugs." This 
publication also emphasizes that T-61 is of limited use because "a major 
limitation ... is that it should be injected only intravenously and not 
administered by any other route; an additional limitation is that it 
should be administered at a precise rate. Not only does the skill of the 
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euthanasia technician vary from person to person, but the reactions of 
the animals are variable and unpredictable." 
This publication approves of sodium pentobarbital as the best 
euthanasia method available and endorses the use of FP-3 (sodium 
pentobarbital plus lidocaine), the added benefit being that this is easier 
to obtain as a Schedule III drug rather than Schedule II as sodium 
pentobarbital is classified. 
Further evidence in support ofT-61 being rejected as being an unsatis-
factory and unreliable euthanasia compound comes from the United 
Kingdom, where T-61 is not accepted by the veterinary profession. British 
veterinarian Deborah J. Baker, employed by Hoechst Company, manufac-
turers of T-61 states, in a letter to The HSUS (7 August 1980): 
" ... for the last four years, this product has been unavailable in the 
UK. It was withdrawn because although for Euthanasia the mode of 
action seems good, in practice, I gather that animals euthanized with 
this tended to have rather distressing, painful convulsions accompanied 
by howling prior to their demise, this being because the phases, i.e. 
induction stage, anaesthetic stage and respiratory paralysis do not occur 
in that order, and one tends to get respiratory paralysis prior to anaes-
thesia being completed. I, myself, therefore, would not recommend its 
use for euthanasia purposes." 
A study by Dr. William Lumb comparing T-61 and sodium pentobar-
bital published in the Journal of the American Veterinary Medical 
Association comparing the effects of sodium pentobarbital and T-61 
(January 15, 1968) is often cited as showing that T-61 is superior because 
some of the dogs given sodium pentobarbital did not die. While it might 
be unfair to suggest that this study, funded by the manufacturers of 
T-61, was rigged to ensure a favorable outcome for them, it is obvious 
that the investigator avoided overdosing the dogs with sodium pentobar-
bital in order to ensure that they would not recover, which is common 
practice when using this drug for euthanasia. Dr. Lumb used a weaker 
(anaesthetic-surgery) strength solution of sodium pentobarbital in this 
study, than is routinely used when this drug is employed for euthanasia. 
Little wonder therefore that some dogs recovered. 
It is obvious from the above evidence, and in view of the fact that 
there are more humane alternatives to using T-61 as a euthanasia agent, 
that T-61 should not be approved for euthanasia purposes in animal 
shelters. Nor should it be recognized as an acceptable agent of euthanasia. 
